Diabetes Mellitus Type 2

Riomet recall: Sun Pharma warns against diabetes drug contamination

28-Nov-2017 By Flora Southey

Sun Pharma has recalled two lots of its type 2 diabetes treatment Riomet, citing microbial contamination.

Novo Nordisk and Sanofi diabetes combo drugs receive US recommendation

26-May-2016 By Dan Stanton

The US FDA has voted in favour of two combination type 2 diabetes drugs putting Novo Nordisk and Sanofi head-to-head in a crowded market.

Chiltern seeking metabolism expertise for new unit after hiring ex PPD exec

05-Oct-2015 By Dan Stanton

Got experience in endocrinology and metabolism indications R&D? Chiltern has added a new offering and says it is looking to hire.

Sanofi Q2 Afrezza sales far from a giant leap for MannKind

30-Jul-2015 By Dan Stanton

The €3m Afrezza has contributed to Sanofi’s revenues since launch is unlikely to subdue growing concerns from commentators surrounding its partner MannKind which developed the inhalable insulin.

GSK, Cold Spring Harbor Laboratory to develop obesity, Type 2 diabetes treatment

23-Mar-2015 By Zachary Brennan

Cold Spring Harbor Laboratory (CSHL) will collaborate with GlaxoSmithKline to develop treatments for obesity and Type 2 diabetes. 

New device should reduce risk posed by high-dose insulin

29-Oct-2012

A new delivery device should reduce the risk posed by the availability of high-dose insulin in Europe say regulators, but vigilance is still needed.

Sanofi investment targets China’s diabetes market

21-Apr-2009 By Nick Taylor

Sanofi-Aventis is investing a further $90m in its Chinese manufacturing facility and performing “the world’s largest diabetes genotyping project” in partnership with the Chinese Diabetes Society.

Merck confirms diabetes retreat

12-Dec-2007 By Kirsty Barnes

Merck Serono intends to forge ahead with severing its investment in
diabetes and either sell or partner out its existing research and
development (R&D) activities in this field, which it no longer
feels able to compete in effectively.

New safety warning delays Novartis diabetes drug

06-Nov-2007 By Anna Lewcock

Swiss firm Novartis today announced that it has contacted
regulators regarding the safety of the 100mg dose of its recently
approved Type II diabetes drug, Galvus (vildagliptin).

Merck KGaA pulls out of diabetes research

24-Oct-2007 By staff reporter

In a shock announcement at its third quarter financial results,
Merck KGaA has said it will stop its diabetes research and partner
out any current programmes.

Novartis diabetes drug gets thumbs up in EU

01-Oct-2007 By Katrina Megget

Novartis's potential Type II diabetes blockbuster has been given
the green light in the EU after receiving approval.

Sanofi-Aventis faces a second patent lawsuit for SoloStar

28-Aug-2007 By Katrina Megget

Sanofi-Aventis has been hit with its second patent lawsuit in two
months over its recently released SoloStar insulin pen.

Sanofi-Aventis gets US OK for disposable insulin pen

02-May-2007 By Pete Mansell

US diabetics will soon have a new alternative to the predominant
needle and syringe method of administering insulin, now that the
Food and Drug Administration (FDA) has granted marketing approval
to Sanofi-Aventis' Lantus SoloStar.

SoloStar insulin pen to debut on ease-of-use platform

21-Mar-2007 By Peter Mansell

Sanofi-Aventis is gearing up for the European roll-out of a new
disposable insulin pen designed to address a broader spectrum of
patient needs than currently available injection devices.

Alantos initiates Phase I study for DPP-IV diabetes drug

21-Aug-2006 By Wai Lang Chu

Alantos Pharmaceuticals has initiated a Phase I trial for its lead
compound for diabetes, a disease that commands a global market
estimated at $11bn (€8.6bn) and is expected to grow by more than 50
per cent by the end of the decade.